Results 21 to 30 of about 3,776 (143)

Locoregional melanoma metastases resistant to PD-1 inhibitor therapy treated with intralesional talimogene laherparepvec [PDF]

JAAD Case Reports
Matthew M. Wallace, MD, John A. Zitelli, MD   +1 more
doaj   +2 more sources

A phase I study of the safety and efficacy of talimogene laherparepvec in Japanese patients with advanced melanoma [PDF]

Cancer Science, 2022
Hiroshi Koga, Satoshi Fukushima, Takashi Kojima   +2 more
exaly   +2 more sources

Final 5-Year Follow-Up Results Evaluating Neoadjuvant Talimogene Laherparepvec Plus Surgery in Advanced Melanoma: A Randomized Clinical Trial.

JAMA Oncol, 2023
This randomized clinical trial presents the final 5-year follow-up results of neoadjuvant talimogene laherparepvec (T-VEC) plus surgery in patients with advanced ...
Dummer R, Gyorki DE, Hyngstrom JR, Ning M, Lawrence T, Ross MI.   +5 more
europepmc   +2 more sources

Talimogene laherparepvec (T-VEC) and Emerging Intralesional Immunotherapies for Metastatic Melanoma: A Review. [PDF]

Curr Oncol Rep
PURPOSE OF REVIEW: As the incidence of cutaneous melanoma continues to rise worldwide, its heterogeneous presentation proves challenging for managing and preventing relapse.
Kalsi S, Galenkamp AL, Singh R, Khosla AA, McGranaghan P, Cintolo-Gonzalez J.   +5 more
europepmc   +4 more sources

Complete resolution of PD-1 refractory, locoregionally advanced Merkel cell carcinoma with talimogene laherparepvec [PDF]

JAAD Case Reports, 2023
Neha Singh, BS, Erin McClure, BS, Coley Doolittle-Amieva, PA-C, Upendra Parvathaneni, MD, Shailender Bhatia, MD, Ata S. Moshiri, MD, MPH   +5 more
doaj   +2 more sources

Talimogene Laherparepvec (T-VEC): A Review of the Recent Advances in Cancer Therapy. [PDF]

J Clin Med, 2023
The landscape of melanoma treatment has undergone a dramatic revolution in the past decade. The use of oncolytic viruses (OVs) represents a novel therapeutic approach that can selectively infect and lyse tumor cells and induce local and systemic ...
Zhang T, Jou TH, Hsin J, Wang Z, Huang K, Ye J, Yin H, Xing Y.   +7 more
europepmc   +2 more sources

Vaccinating against cancer: getting to prime time

Journal for ImmunoTherapy of Cancer, 2023
Immunotherapies, such as immune checkpoint inhibitors, cellular therapies, and T-cell engagers, have fundamentally changed our approach to treating cancer. However, successes with cancer vaccines have been more difficult to realize.
Lawrence Fong, Ryan Chang
doaj   +1 more source

Use of Talimogene Laherparepvec to Treat Cutaneous Squamous Cell Carcinoma in a Renal Transplant Patient. [PDF]

Case Rep Dermatol, 2023
A 66-year-old female with a history of two renal transplants due to recurrent thrombotic thrombocytopenic purpura presented to clinic with multiple lesions identified to be non-metastatic cutaneous squamous cell carcinoma (CSCC).
Miller M, Kim NH, Thosani MK, Moser JC.
europepmc   +2 more sources

Commentary on oncolytic viruses: past, present, and future

Journal for ImmunoTherapy of Cancer, 2023
Whither oncolytic viruses? From the peak of their popularity in the early 2000s, when the ONYX-015 adenovirus had just entered the clinic, and then again in 2015 when the Food and Drug Administration-approved talimogene laherparepvec (also known as ...
Christopher Larson, Bryan Oronsky, Tony R Reid   +2 more
doaj   +1 more source

Complete tumour regression of in-transit melanoma following discontinuation of talimogene laherparepvec. [PDF]

BMJ Case Rep
We report a case of complete tumour regression in a man in his 80s with in-transit melanoma following discontinuation of talimogene laherparepvec (T-VEC). The patient underwent a standard course of 1.0 mL of 1×10⁸ pfu/mL T-VEC every 2 weeks.
Chen AS, Proia AD, Ho L, Mosca P.
europepmc   +2 more sources